Lebanon, NH: National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has awarded a Phase II Small Business Innovation Research (SBIR) Fast-Track grant to Celdara Medical. This award supports the ongoing development of CM-IAV1, a promising therapeutic antibody designed to treat high-priority influenzas that have the potential to cause pandemics.
Influenzas with high morbidity and mortality and/or high transmissibility are a significant public health concern. With the support of NIAID and the dedication of its expert team, Celdara Medical aims to advance what may become an important component of preparedness for the benefit of global health and public safety.
“Given the impact and lessons from COVID-19, the urgent need for effective treatments for high-risk pandemic influenzas cannot be overstated,” said Dr. Jake Reder, Co-founder and Chief Executive Officer of Celdara Medical. “We are grateful to NIAID for their support, which validates our innovative approach in tackling infectious diseases. This funding will facilitate the continued development of CM-IAV1, bringing us closer to our goal of combatting high-risk pandemic influenzas.”
Dr. Colleen Cooper, Principal Investigator on the project and Principal Scientist at Celdara Medical, remarked, “Pandemic influenzas are a unique threat to global health security, particularly for vulnerable populations. NIAID’s support underscores the significance of our work in developing CM-IAV1, a potential game-changer in treating high-risk pandemic influenzas. We are thrilled to have the opportunity to advance this promising therapy and to make a positive impact on public health.”
This project builds upon the groundbreaking research performed at the University of Chicago by Dr. Patrick Wilson, now a Professor at Weill Cornell Medical School. Dr. Wilson will continue to provide critical scientific guidance to the project.
Research reported in this press release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number 4R44AI157074-02. The content is solely the responsibility of Celdara Medical and does not necessarily represent the official views of the National Institutes of Health.
About Celdara Medical, LLC
Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008 and is headquartered at the Dartmouth Regional Technology Center (DRTC) in Lebanon, NH. Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health. Further information about Celdara Medical is available at www.celdaramedical.com.